BTQ Technologies has finalized its acquisition of QPerfect, a French quantum computing firm known for its MIMIQ™ quantum emulator, Digital Twin system modeling, and Quantum Logical Unit control framework. This acquisition enhances BTQ's technology stack to support secure, scalable quantum systems and advances its mission to build trusted quantum technologies. Regulatory approval from French authorities came with commitments to maintain QPerfect's operations in France and protect its intellectual property. The deal includes a combination of cash and BTQ shares, with additional earnout payments tied to milestones. BTQ aims to leverage QPerfect's innovations to prepare networks for quantum-safe cryptography and hybrid quantum-classical environments, especially in defense and telecommunications sectors.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
